Income statement
GBP
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 23.7B | 22.6B | 16.9B |
| Gross Profit | 670K | 2M | 5M | 3M | 3M |
| Operating Income | -2M | -2M | 2M | 412K | 549K |
| EBITDA | -2M | -1M | 2M | 625K | 714K |
| Net Income | -3M | -2M | 1M | 72K | 295K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.02
+0.00% today
1Y Change
-50.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Proteome Sciences plc (PMSNF) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 50.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -23.2%, EPS growth of +9.6%, a dividend yield of 0.0%. What stands out right now is revenue -23.2%, EPS +9.6%, free cash flow +86.4% with operating margin -71.0% and ROIC -34.3%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PMSNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMSNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMSNF Max Drawdown
-80.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMSNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$16.9B
-25.0% YoY
FY Net Income
$295.0K
+309.7% YoY
Free Cash Flow
-$9.1B
-203.0% YoY
Revenue Growth
-23.2%
EPS Growth
+9.6%
Gross Margin
-26.8%
Net Margin
-81.5%
Income statement
GBP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 23.7B | 22.6B | 16.9B |
| Gross Profit | 670K | 2M | 5M | 3M | 3M |
| Operating Income | -2M | -2M | 2M | 412K | 549K |
| EBITDA | -2M | -1M | 2M | 625K | 714K |
| Net Income | -3M | -2M | 1M | 72K | 295K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 2M | 4M | 2M | 2M |
| Total Assets | 9M | 11M | 12M | 10M | 9M |
| Total Liabilities | 16M | 15M | 13M | 13M | 12M |
| Shareholder Equity | -7M | -3M | -843K | -3M | -3M |
| Total Debt | 15M | 13M | 12M | 12M | 11M |
| Net Debt | 13M | 11M | 8M | 9M | 9M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7.7B
-173.6% YoY
Capital Expenditures
1.3B
+23.0% YoY
Free Cash Flow
9.1B
-203.0% YoY
Key ratios
Gross Margin
-26.8%
Operating Margin
-71.0%
Net Margin
-81.5%
ROE
33.8%
Debt / Equity
-1.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.